Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asphelia Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

In an era of high-tech medicine, of painstakingly designed molecular inhibitors and personalized medicine driven by genetic responses to drugs, Asphelia Pharmaceuticals is placing its bets on a primitive technology: intestinal worms, known as helminthes. Helminthes release proteins that boost the activity of regulatory T-cells, and the antigens they produce appear to influence a variety of targets. Asphelia is developing helminthes as an oral treatment for Crohn's and other autoimmune diseases. Also in the company's pipeline, a novel oral compound that targets integrins in order to treat immunological and inflammatory disorders.
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091598

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel